Education & Experience
- Commenced his training in Medical Oncology at the Mater Hospital, Dublin during which time he completed an MBA in Health Services Management.
- 2000 - 2002 - He went on to The Institut Curie, Paris where he completed a PhD in Tumour Immunology.
- 2002 - 2004 Completed his clinical training at Fox Chase Cancer Center, Philadelphia (2002-2004), where he furthered an interest in Genito-Urinary Oncology. During this training period, he published over twenty peer reviewed articles and Book Chapters.
- 2004 - Took up a post as Consultant Medical Oncologist at the Adelaide Meath & National Childrens Hospital, Tallaght.
Clinical Research & Professional memberships
In 2006, Dr McDermott was instrumental in establishing Ireland as a main member of the Eastern Co-Operative Group, the largest clinical trials group in the USA with over 70 active studies. Dr McDermott is the Principal Investigator for Ireland in this initiative and is involved in twice yearly meetings with ECOG to develop this relationship.
Under the auspices of the National Cancer Control Programme and the establishment of “Centres of Excellence”, Dr McDermott’s public hospital commitment was split between AMNCH and St Vincent’s University Hospital, where he pursues his interest in genito-urinary and gastro-intestinal cancers.
Dr McDermott is the National Cancer ControI Programme leader in guideline development for prostate cancer and sits on the new drug evaluation committee across all diseases. He is the clinical lead of the All Ireland Clinical Oncology Research Group and Chair of the Genito-Urinary Disease Specific Sub-Group. He has personally accrued over 500 patients to clinical trials in the last 5 years and has written 5 studies which are currently open to accrual through ICORG, many in collaboration with industry partners. He has recently opened the first in man combination study of alpharadin and enzalutamide in castrate resistant prostate cancer with support from Bayer and Astellas.
He has formalised a collaboration with the Dana Farber Cancer Institute, ANZUP-the Australian clinical trials group- and the Royal Marsden in two major Phase III clinical trials in prostate cancer involving enzalutamide with ICORG as European sponsor.
